|
Aug 10
|
Cytosorbents Second Quarter 2025 Earnings: Beats Expectations
|
|
Aug 7
|
CytoSorbents: Q2 Earnings Snapshot
|
|
Jul 31
|
CytoSorbents Leads a New Era in Sepsis Treatment
|
|
Jul 29
|
CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights
|
|
Jun 24
|
CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR
|
|
Apr 21
|
CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
|
|
Apr 17
|
CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller
|
|
Jan 13
|
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
|
|
Jan 6
|
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai
|
|
Jan 4
|
CytoSorbents reported strong Q4 results, says D. Boral Capital
|
|
Jan 3
|
CTSO: CytoSorbents Reports Preliminary 4th Quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations.
|
|
Jan 3
|
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
|